Clinical Trial

Study of 18F-FFNP Breast PET/MRI

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This clinical trial will investigate an estrogen-regulated parameter as an early measure of endocrine therapy response: progesterone receptor (PR) protein with a progestin-based radioligand, 18F-fluorofuranylnorprogesterone (18F-FFNP). The overall purpose of this research is to test the efficacy of 18F-FFNP PET/MRI for predicting response to presurgical endocrine therapy and to determine the quantitative reliability of 18F-FFNP breast PET/MRI in patients with newly diagnosed PR+ primary breast cancer.
Protocol Amendment History 14 amendments
This ClinicalTrials.gov record has been amended 14 times since 2023-10-11; most recent amendment 2026-05-14.
Status change: Not Yet Recruiting → Recruiting 2023-12-26
Trial Details
NCT Number NCT06086704
Lead Sponsor University of Wisconsin, Madison
Collaborators: National Cancer Institute (NCI)
Conditions Breast Cancer
Enrollment 53 participants
Start Date 2024-09-25
Primary Completion 2027-01 (estimated)
Study Completion 2030-01 (estimated)
Updated on ClinicalTrials.gov 2026-05-18